A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

Inclusion Criteria: * Men and nonpregnant, nonlactating women were 18 years or older. * Women declaring postmenopausal or surgical sterility. * Women of childbearing potential who had a negative serum HCG within 2 weeks of dosing. * Male subjects weighed at least 60 kg (132 lb), and female subjects weighed at least 48 kg (106 lb). All volunteers weighed within 15% of their ideal body weight (IBW). Exclusion Criteria: * Institutionalized * Reported or was known to have done the following: * Used any tobacco product. * Ingested any alcoholic, caffeine or xanthine containing food or beverage within the 48 hours prior to the initial dose of study medication * Consumed grapefruit or grapefruit containing products within 7 days prior to the initial dose of study medication. * Ingested any vitamins or herbal products within the 48 hours prior to the initial dose of study medication. * Recently changed dietary or exercise habits significantly * Used any medication (including over-the-counter \[OTC\]) within the 14 days prior to the initial dose of study medication. * Used any medication known to alter hepatic enzyme activity within 28 days prior to the initial dose of study medication. * Received an investigational drug within 30 days prior to the initial dose of study medication. * History of any significant cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease. * History of drug and/or alcohol abuse within 1 year prior to the study. * Acute illness at the time of either the pre study medical evaluation or dosing. * Any laboratory results deemed clinically significant by the physician. * Abnormal and clinically relevant ECG tracing. * Donated or lost a significant volume of blood or plasma (\>450 mL) within 28 days prior to the initial dose of study medication. * Allergic or hypersensitive to nebivolol, atenolol, or other β blocking drugs or to moxifloxacin or other quinolone antibiotics. * History of seizures or cerebrovascular disease.